APA (7th ed.) Citation

Chung, V., Devoe, C. E., George, T. J., Welkowsky, E., Kheoh, T., Haqq, C. M., . . . O'Reilly, E. M. (2024). AMPLIFY-7P: Phase 1 and randomized phase 2 study of amphiphile immunotherapy ELI-002 7P as adjuvant treatment for subjects with G12D, G12R, G12V, G12C, G12A, G12S and G13D Kirsten rat sarcoma (KRAS)-mutated pancreatic ductal adenocarcinoma. Journal of clinical oncology, 42(3_suppl), TPS720. https://doi.org/10.1200/JCO.2024.42.3_suppl.TPS720

Chicago Style (17th ed.) Citation

Chung, Vincent, Craig E. Devoe, Thomas J. George, Esther Welkowsky, Thian Kheoh, Christopher M. Haqq, Shubham Pant, and Eileen Mary O'Reilly. "AMPLIFY-7P: Phase 1 and Randomized Phase 2 Study of Amphiphile Immunotherapy ELI-002 7P as Adjuvant Treatment for Subjects with G12D, G12R, G12V, G12C, G12A, G12S and G13D Kirsten Rat Sarcoma (KRAS)-mutated Pancreatic Ductal Adenocarcinoma." Journal of Clinical Oncology 42, no. 3_suppl (2024): TPS720. https://doi.org/10.1200/JCO.2024.42.3_suppl.TPS720.

MLA (9th ed.) Citation

Chung, Vincent, et al. "AMPLIFY-7P: Phase 1 and Randomized Phase 2 Study of Amphiphile Immunotherapy ELI-002 7P as Adjuvant Treatment for Subjects with G12D, G12R, G12V, G12C, G12A, G12S and G13D Kirsten Rat Sarcoma (KRAS)-mutated Pancreatic Ductal Adenocarcinoma." Journal of Clinical Oncology, vol. 42, no. 3_suppl, 2024, p. TPS720, https://doi.org/10.1200/JCO.2024.42.3_suppl.TPS720.